Giant Axonal Neuropathy Market: Analysis of Epidemiology, Pipeline Products, and Key Pharma Players Working in the Market | Companies – Taysha Gene Therapies

September 15 01:50 2023
Giant Axonal Neuropathy Market: Analysis of Epidemiology, Pipeline Products, and Key Pharma Players Working in the Market | Companies - Taysha Gene Therapies
Giant Axonal Neuropathy Market
DelveInsight’s “Giant Axonal Neuropathy (GAN) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Giant Axonal Neuropathy (GAN), historical and forecasted epidemiology as well as the Giant Axonal Neuropathy (GAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on Giant Axonal Neuropathy – Market Insights, Epidemiology, and Market Forecast-2032”.

Some of the key facts of the Giant Axonal Neuropathy Market Report:

  • According to a Japanese case study by Koichihara et al. (2016), mild GAN, particularly in the early stages, can be misdiagnosed because of lack of typical hair features and incomplete or indistinct peripheral and central nervous system symptoms. This case is important since it can aid to identify atypical and milder clinical courses of GAN.
  • Laguna et al. (2020), in a multicenter observational retrospective study, recorded French patients with GAN mutations, and 10 patients were identified. The mean age of patients was 9.7 years (2–18), and all patients met infant developmental milestones and had a family history of consanguinity. The mean age at disease onset was 3.3 years (1–5), and patients used a wheelchair at a mean age of 16 years (14–18). Patients also showed a variety of associated findings, including curly hair (100% of cases), pes cavus (80%), ophthalmic abnormalities (30%), and scoliosis (30%). Five new GAN mutations were found, including the first synonymous mutation and a large intragenic deletion.

Key benefits of the report:

  1. Giant Axonal Neuropathy market report covers a descriptive overview and comprehensive insight of the Giant Axonal Neuropathy Epidemiology and Giant Axonal Neuropathy  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Giant Axonal Neuropathy market report provides insights into the current and emerging therapies.
  3. Giant Axonal Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Giant Axonal Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Giant Axonal Neuropathy market.

Giant Axonal Neuropathy Overview

Giant axonal neuropathy (GAN) is a rare inherited genetic disorder that severely affects the peripheral as well as the central nervous system. GAN is characterized by abnormally large and dysfunctional axons called giant axons. The onset of GAN ranges from early infancy to late childhood

This neurodegenerative disorder is caused by mutations in the GAN gene located on chromosome 16 at 16q24.1 which provides instructions for making a protein called gigaxonin protein. The nonstandard gigaxonin protein causes a portion of the nerve cell called the axon to swell up with deposits of tiny threads of a protein called neurofilaments, giving the presence of giant axons. The giant axons cause degeneration and abnormal functioning of the peripheral nervous system. This condition is inherited in an autosomal recessive pattern, which means both copies of the gene present in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they usually do not show signs and symptoms of the condition. As per some studies, since the first GAN report in 1972, more than 50 GAN gene mutations have been identified.

Giant Axonal Neuropathy Market 

The dynamics of the Giant Axonal Neuropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Taysha Gene Therapies and others during the study period 2019-2032.

Learn more by requesting for sample @ Giant Axonal Neuropathy Market Landscape

Giant Axonal Neuropathy Pipeline Therapies and Key Companies 

  • TSHA-120: Taysha Gene Therapies

Giant Axonal Neuropathy Market Drivers 

  • Active participation of the different organization in increased R&D
  • Regulatory incentives such as market exclusivity for orphan designated drugs

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Giant Axonal Neuropathy Patient Share (%) Overview at a Glance

5. Giant Axonal Neuropathy Market Overview at a Glance

6. Giant Axonal Neuropathy Disease Background and Overview

7. Giant Axonal Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Giant Axonal Neuropathy 

9. Giant Axonal Neuropathy Current Treatment and Medical Practices

10. Unmet Needs

11. Giant Axonal Neuropathy Emerging Therapies

12. Giant Axonal Neuropathy Market Outlook

13. Country-Wise Giant Axonal Neuropathy Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Giant Axonal Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Giant Axonal Neuropathy Market Outlook 2032.

Related Reports:

Giant Axonal Neuropathy Pipeline 

Giant Axonal Neuropathy Epidemiology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States